肝癌术后复发危险因素研究进展

doi:10.3969/j.issn.1009-976X.2023.03.011

摘要/Abstract

摘要： 肝细胞癌（HCC）是最常见的癌症之一。目前根治性肝切除术仍是HCC的主要治疗手段,尽管在HCC患者的监测、诊断和治疗方面取得了相当大的进展,但HCC根治性肝切除术后高复发率仍居高不下。影响HCC术后复发的危险因素很多,目前可将HCC术后复发相关危险因素分为宿主因素、肿瘤因素和手术因素。本文将对HCC根治性切除术后复发危险因素研究进展进行综述,为临床工作者提供参考。

关键词: 肝细胞癌, 根治性肝切除术, 复发, 危险因素, 研究进展

Abstract: Hepatocellular carcinoma （HCC） is one of the most common cancers. At present, radical hepatectomy is still the main treatment for HCC. Although considerable progress has been made in the monitoring, diagnosis and treatment of HCC patients, the high recurrence rate after radical hepatectomy remains high. There are many risk factors affecting the recurrence of HCC after operation. At present, the risk factors related to the recurrence of HCC after operation can be divided into host factors, tumor factors and surgical factors. This article will review the research progress of risk factors for recurrence after radical resection of HCC, and provide reference for clinical workers.

Key words: hepatocellular carcinoma, radical hepatectomy, recurrence, risk factors, research progress

中图分类号:

R735.7

刘丽清, 张黎, 金焰, 徐敬. 肝癌术后复发危险因素研究进展[J]. 岭南现代临床外科, 2023, 23(03): 269-276.

LIU Li-qing, ZHANG Li, JIN Yan, XU Jing. Research progress on risk factors of postoperative recurrence of liver cancer[J]. Lingnan Modern Clinics In Surgery, 2023, 23(03): 269-276.

参考文献

[1] Xie DY, Ren ZG, Zhou J, et al.2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights[J]. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463.
[2] Xia C, Dong X, Li H, et al.Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
[3] Siegel RL, Miller KD, Fuchs HE, et al.Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[4] Zeng H, Chen W, Zheng R, et al.Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567.
[5] Gou H, Liu S, Zhu G,et al.Effectiveness of radiofrequency ablation versus transarterial chemoembolization for recurrent hepatocellular carcinoma: A meta-analysis[J]. Acta Radiol Open, 2022, 11(3): 20584601221085514.
[6] Erstad DJ, Tanabe KK.Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2019, 26(5): 1474-1493.
[7] Huang ZY, Liang BY, Xiong M, et al.Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China[J]. Ann Surg Oncol, 2012, 19(8): 2515-2525.
[8] Heimbach JK, Kulik LM, Finn RS, et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380.
[9] Kobayashi A, Miyagawa S, Miwa S, et al.Prognostic impact of anatomical resection on early and late intrahepatic recurrence in patients with hepatocellular carcinoma[J]. J Hepatobiliary Pancreat Surg, 2008, 15(5): 515-521.
[10] Poon RT, Fan ST, Ng IO, et al.Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma[J]. Cancer, 2000, 89(3): 500-507.
[11] Poon RT.Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies[J]. Ann Surg Oncol, 2009, 16(4): 792-794.
[12] Zhou KQ, Sun YF, Cheng JW, et al. Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma [J]. EBioMedicine, 2020, 62(103107.
[13] Liu WC, Liu QY.Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(20): 6252-6261.
[14] Jin H, Wang H, Li G, et al.Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma[J]. J Int Med Res, 2020, 48(10): 300060520961260.
[15] Cheng Z, Yang P, Lei Z, et al.Nomograms for prediction of long-term survival in elderly patients after partial hepatectomy for hepatocellular carcinoma[J]. Surgery, 2017, 162(6): 1231-1240.
[16] Sohn W, Paik YH, Kim JM, et al.HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma[J]. Ann Surg Oncol, 2014, 21(7): 2429-2435.
[17] Kim BW, Kim YB, Wang HJ, et al.Risk factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma[J]. World J Gastroenterol, 2006, 12(1): 99-104.
[18] Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma[J]. Ann Surg, 2000, 232(1): 10-24.
[19] Wu JC, Huang YH, Chau GY, et al.Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma[J]. J Hepatol, 2009, 51(5): 890-897.
[20] Trépo C, Chan HL, Lok A.Hepatitis B virus infection[J]. Lancet, 2014, 384(9959): 2053-2063.
[21] Chen L, Zhang Q, Chang W, et al.Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma[J]. Eur J Cancer, 2012, 48(13): 1977-1987.
[22] Wei X, Li N, Li S, et al.Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma[J]. BMC Cancer, 2017, 17(1): 304.
[23] Li Z, Lei Z, Xia Y, et al.Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma[J]. JAMA Surg, 2018, 153(10): e182721.
[24] Hung IF, Poon RT, Lai CL, et al.Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection[J]. Am J Gastroenterol, 2008, 103(7): 1663-1673.
[25] Wang MD, Li C, Liang L, et al.Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma[J]. Oncologist, 2020, 25(10): e1541-e51.
[26] Li QM, Zhou HB, Hu HP, et al.The influence of HBsAg expression in liver tissue on the postoperative recurrence of HCC patients[J]. Zhonghua Zhong Liu Za Zhi, 2022, 44(4): 347-353.
[27] Liu WR, Tian MX, Jin L, et al.High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads[J]. Ann Surg Oncol, 2015, 22(3): 843-850.
[28] Qiu JF, Ye JZ, Feng XZ, et al.Pre- and post-operative HBsAg levels may predict recurrence and survival after curative resection in patients with HBV-associated hepatocellular carcinoma[J]. J Surg Oncol, 2017, 116(2): 140-148.
[29] Lee IC, Lei HJ, Chau GY, et al.Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg[J]. Am J Cancer Res, 2021, 11(7): 3711-3725.
[30] Yoo S, Kim JY, Lim YS, et al.Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection[J]. J Hepatol, 2022, 77(4): 939-946.
[31] Yang Y, Gao J, Tan YT, et al.Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk[J]. J Gastroenterol Hepatol, 2018, 33(5): 1131-1137.
[32] 李巧媚,周华邦,胡和平,等.肝组织内乙型肝炎表面抗原阳性对肝细胞癌术后复发的影响[J].中华肿瘤杂志,2022,44(4):347-353.
[33] Qu LS, Liu JX, Zhu J, et al.Risk Factors for Prognosis of Hepatocellular Carcinoma After Curative Resection In Patients with Low Hepatitis B Viral Load[J]. Ann Hepatol, 2017, 16(3): 412-420.
[34] Zhang L, Xie XY, Chen Y, et al.Hepatitis B surface antigen predicts recurrence after radiofrequency ablation in patients with low hepatitis B virus loads[J]. Medicine (Baltimore), 2017, 96(52): e9377.
[35] Cucchetti A, Piscaglia F, Caturelli E, et al.Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population[J]. Ann Surg Oncol, 2009, 16(2): 413-422.
[36] Miyata T, Matsumoto T, Nakao Y, et al.Major postoperative complications are associated with early recurrence of hepatocellular carcinoma following hepatectomy[J]. Langenbecks Arch Surg, 2022, 407(6): 2373-2380.
[37] Yan WT, Li C, Yao LQ, et al.Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study[J]. Hepatobiliary Surg Nutr, 2023, 12(2): 155-168.
[38] Liu H, Cen D, Yu Y, et al.Does fibrosis have an impact on survival of patients with hepatocellular carcinoma: evidence from the SEER database?[J]. BMC Cancer, 2018, 18(1): 1125.
[39] Gu J, Zhang E, Liang B, et al.Liver Collagen Contents Are Closely Associated with the Severity of Cirrhosis and Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma and Child-Pugh Grade A Liver Function[J]. Ann Surg Oncol, 2021, 28(8): 4227-4235.
[40] Arvaniti V, D'Amico G, Fede G,et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis [J]. Gastroenterology, 2010, 139(4): 1246-1256, 56.e1-5.
[41] Kamiyama T, Nakanishi K, Yokoo H,et al.Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma[J]. World J Surg Oncol, 2012, 10(107).
[42] Tokumitsu Y, Sakamoto K, Tokuhisa Y, et al.A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy[J]. Oncol Lett, 2018, 15(4): 4411-4422.
[43] Tokumitsu Y, Shindo Y, Matsui H, et al.Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy[J]. Oncol Lett, 2019, 18(4): 3903-3913.
[44] Zhu F, Yang F, Li J, et al.Incomplete tumor capsule on preoperative imaging reveals microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis[J]. Abdom Radiol (NY), 2019, 44(9): 3049-3057.
[45] Kim H, Park MS, Park YN, et al.Preoperative radiologic and postoperative pathologic risk factors for early intra-hepatic recurrence in hepatocellular carcinoma patients who underwent curative resection[J]. Yonsei Med J, 2009, 50(6): 789-795.
[46] Hu J, Zhang ZQ, Zhu W, et al.Comparison of clinicopathological traits and prognostic factors of hepatocellular carcinoma with and without cirrhotic background[J]. Carcinogenesis, 2020, 41(11): 1576-1582.
[47] Sun YF, Xu Y, Yang XR, et al.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4): 1458-1468.
[48] Chou CT, Chen RC, Lee CW, et al.Prediction of microvascular invasion of hepatocellular carcinoma by pre-operative CT imaging[J]. Br J Radiol, 2012, 85(1014): 778-783.
[49] Dai H, Lu M, Huang B, et al.Considerable effects of imaging sequences, feature extraction, feature selection, and classifiers on radiomics-based prediction of microvascular invasion in hepatocellular carcinoma using magnetic resonance imaging[J]. Quant Imaging Med Surg, 2021, 11(5): 1836-1853.
[50] Chong HH, Yang L, Sheng RF, et al.Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm[J]. Eur Radiol, 2021, 31(7): 4824-4838.
[51] Xu X, Zhang HL, Liu QP, et al.Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma[J]. J Hepatol, 2019, 70(6): 1133-1144.
[52] Lei Z, Li J, Wu D, et al.Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan Criteria[J]. JAMA Surg, 2016, 151(4): 356-363.
[53] Uchino K, Tateishi R, Shiina S, et al.Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors[J]. Cancer, 2011, 117(19): 4475-4483.
[54] Cheng Z, Yang P, Qu S, et al.Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection[J]. HPB (Oxford), 2015,17(5):422-427.
[55] Lu Y, Zhu M, Li W, et al.Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells[J]. J Cell Mol Med, 2016,20(3):549-558.
[56] Mouchli M, Reddy S, Gerrard M, et al.Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article[J]. Ann Hepatol, 2021,22:100249.
[57] Shindoh J, Hasegawa K, Inoue Y, et al.Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma[J]. HPB (Oxford), 2013,15(1):31-9.
[58] Zhu HT, Liu RB, Liang YY, et al.Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma[J]. Liver Int, 2017,37(6):888-896.
[59] Zhou J, Yu L, Gao X, et al.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011,29(36):4781-4788.
[60] Beppu T, Sugimoto K, Shiraki K, et al.Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation[J]. Int J Mol Med, 2010,26(3):425-433.
[61] Chen Q, Li F, Zhong C, et al.Inflammation Score System using Preoperative Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma after Hepatectomy: A Cohort Study[J]. J Cancer, 2020,11(17):4947-4956.
[62] Ramakrishna G, Rastogi A, Trehanpati N, et al.From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence[J]. Liver Cancer, 2013, 2(3-4):367-383.
[63] Hung HC, Lee JC, Cheng CH, et al.Impact of neutrophil to lymphocyte ratio on survival for hepatocellular carcinoma after curative resection[J]. J Hepatobiliary Pancreat Sci, 2017, 24(10):559-569.
[64] Liao R, Tang ZW, Li DW, et al.Preoperative neutrophil-to-lymphocyte ratio predicts recurrence of patients with single-nodule small hepatocellular carcinoma following curative resection: a retrospective report[J]. World J Surg Oncol, 2015, 13:265.
[65] Shimoda M, Tago K, Shiraki T, et al.Risk Factors for Early Recurrence of Single Lesion Hepatocellular Carcinoma After Curative Resection[J]. World J Surg, 2016, 40(10):2466-2471.
[66] Lee SK, Lee SW, Jang JW, et al.Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma[J]. Int J Mol Sci, 2021, 22(19):10271.
[67] Yu Y, Song J, Zhang R, et al.Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict microvascular invasion in patients with hepatocellular carcinoma[J]. Oncotarget, 2017, 8(45):79722-79730.
[68] Wong L, Bozhilov K, Hernandez B, et al.Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio[J]. Clin Mol Hepatol, 2019, 25(3):305-316.
[69] Hagerling C, Werb Z.Neutrophils: Critical components in experimental animal models of cancer[J]. Semin Immunol, 2016, 28(2):197-204.
[70] Mao S, Yu X, Sun J, et al.Development of nomogram models of inflammatory markers based on clinical database to predict prognosis for hepatocellular carcinoma after surgical resection[J]. BMC Cancer, 2022, 22(1):249.
[71] 夏永祥, 张峰, 李相成, 等. 原发性肝癌10 966例外科治疗分析[J]. 中华外科杂志, 2021, 59(1): 6-17.
[72] Hidaka M, Eguchi S, Okuda K, et al.Impact of Anatomical Resection for Hepatocellular Carcinoma With Microportal Invasion (vp1): A Multi-institutional Study by the Kyushu Study Group of Liver Surgery[J]. Ann Surg, 2020, 271(2):339-346.
[73] Tsilimigras DI, Sahara K, Moris D, et al.Effect of Surgical Margin Width on Patterns of Recurrence among Patients Undergoing R0 Hepatectomy for T1 Hepatocellular Carcinoma: An International Multi-Institutional Analysis[J]. J Gastrointest Surg, 2020, 24(7):1552-1560.
[74] Liu L, Shui Y, Yu Q, et al.Narrow-Margin Hepatectomy Resulted in Higher Recurrence and Lower Overall Survival for R0 Resection Hepatocellular Carcinoma[J]. Front Oncol, 2021, 10:610636.
[75] Michelakos T, Kontos F, Sekigami Y, et al.Hepatectomy for Solitary Hepatocellular Carcinoma: Resection Margin Width Does Not Predict Survival[J]. J Gastrointest Surg, 25(7):1727-1735.
[76] Gruttadauria S, Pagano D, Corsini LR, et al.Impact of margin status on long-term results of liver resection for hepatocellular carcinoma: single-center time-to-recurrence analysis[J]. Updates Surg, 2020, 72(1):109-117.
[77] Andreou A, Knitter S, Schmelzle M, et al.Recurrence at surgical margin following hepatectomy for colorectal liver metastases is not associated with R1 resection and does not impact survival[J]. Surgery, 2021, 169(5):1061-1068.
[78] Han J, Li ZL, Xing H, et al.The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study[J]. HPB (Oxford), 2019, 21(8):962-971.
[79] He Y, Fang D, Liang T, et al.Laparoscopic versus open hepatectomy for hepatocellular carcinoma with cirrhosis: a single-center propensity score matching analysis[J]. Ann Transl Med, 2021, 9(23):1733.
[80] Chen J, Bai T, Zhang Y, et al.The safety and efficacy of laparoscopic and open hepatectomy in hepatocellular carcinoma patients with liver cirrhosis: a systematic review[J]. Int J Clin Exp Med, 2015, 8(11):20679-20689.
[81] Tsai KY, Chen HA, Wang WY, et al.Long-term and short-term surgical outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma: might laparoscopic approach be better in early HCC?[J]. Surg Endosc, 2019, 33(4):1131-1139.
[82] Nassar A, Hobeika C, Lamer C, et al.Relevance of blood loss as key indicator of the quality of surgical care in laparoscopic liver resection for colorectal liver metastases[J]. Surgery, 2020, 168(3):411-418.
[83] Tranchart H, O'Rourke N, Van Dam R, et al. Bleeding control during laparoscopic liver resection: a review of literature[J]. J Hepatobiliary Pancreat Sci, 2015, 22(5):371-378.
[84] Lv X, Zhang L, Yu H, et al.Laparoscopic hepatectomy for hepatocellular carcinoma: short- and long-term outcomes with blood loss[J]. Transl Cancer Res, 2021, 10(10):4303-4315.
[85] Gupta R, Fuks D, Bourdeaux C, et al.Impact of intraoperative blood loss on the short-term outcomes of laparoscopic liver resection[J]. Surg Endosc, 2017, 31(11):4451-4457.
[86] Wada H, Eguchi H, Nagano H, et al.Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis[J]. Surg Today, 2018, 48(1):73-79.
[87] Chen GX, Qi CY, Hu WJ, et al. Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma [J]. BMC Cancer, 2020, 29;20(1):487.
[88] Yang T, Lu JH, Lau WY, et al.Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis[J]. J Hepatol, 2016, 64(3):583-593.
[89] Yamashita YI, Hayashi H, Imai K, et al.Perioperative Allogeneic Blood Transfusion Does not Influence Patient Survival After Hepatectomy for Hepatocellular Carcinoma: A Propensity Score Matching Analysis[J]. World J Surg, 2019, 43(11):2894-2901.